China’s 3rd Round of Volume-Based Procurement Includes 56 Drugs, 86 Product Specifications

Region: ASIA & SOUTH PACIFIC | Type: Policy | Keywords: #apo #generics #gqce #procurement #vbp #volumebasedprocurement


PRICENTRIC BRIEF:
  • The Allied Purchase Office (APO) has announced that it is starting to collect essential data on the proposed list of products for China’s third go at national volume-based procurement (VBP) of medicines
  • This list includes 56 drugs by generic name with 86 product specifications
  • China first trialed volume-based procurement in 11 cities (the 4+7 Tender Trial), and in January, it wrapped up its second round of centralized procurement, which resulted in the purchase of 33 drugs regarding 50 specifications, with some medicines purchased at high discounts upwards of 80%

THE DETAILS

BEIJING, China – The Allied Purchase Office (APO) has announced that it is starting to collect essential data on the proposed list of products for China’s third go at national volume-based procurement (VBP) of medicines.

This list includes 56 drugs by generic name with 86 product specifications.

Reportedly, provincial governments have already submitted their proposed purchase volume for the third round.

To be eligible for inclusion in the third VBP, products must be either an originator drug or reference formulations for generic quality and clinical evaluation (GQCE); drugs passing GQCE; generics approved under China’s new chemical drug registration application classification; and be listed on the China Marketed Drug Formulary or China Orange Book.

Domestic manufacturers, marketing authorization holders (MAHs), and foreign pharmaceutical companies with subsidiaries in China or designated representatives with relevant responsibilities can partake in the 3rd VBP.

China first trialed volume-based procurement in 11 cities (the 4+7 Tender Trial) to purchase necessary and widely-used medicines in China’s public hospitals. Through the trial, China secured medicines at significant discounts by requesting discounts for access to its population.

In January, China wrapped up its second round of centralized procurement, which resulted in the purchase of 33 drugs regarding 50 specifications. Over 120 pharmaceutical companies partook in the bidding, which resulted in China purchasing some medicines at high discounts – upwards of 80%.

To see which drugs are to be included in the 3rd round of VBP, click here.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.